Radiotherapy is an important part of the standard treatment regimen for rectal cancer, bringing survival benefits and improved quality of life to patients with rectal cancer. However, the radiotherapy resistance of rectal cancer patients greatly limits the effectiveness of treatment and affects the prognosis of patients. The emergence of nanoparticles provides a new way to improve radiotherapy resistance of rectal cancer, which can overcome radiotherapy resistance by inhibiting DNA damage repair, affecting cell cycle, targeting delivery, enhancing DNA damage, and regulating tumor microenvironment, etc. In this article, complex coordination mechanism leading to radiotherapy resistance in rectal cancer was reviewed, current relevant studies on nanoparticles in improving radiotherapy response in rectal cancer were summarized, and the feasibility and future research direction of the combination of nanoparticles and radiotherapy in clinical treatment of rectal cancer were discussed.

Radiotherapy is an important part of the standard treatment regimen for rectal cancer, bringing survival benefits and improved quality of life to patients with rectal cancer. However, the radiotherapy resistance of rectal cancer patients greatly limits the effectiveness of treatment and affects the prognosis of patients. The emergence of nanoparticles provides a new way to improve radiotherapy resistance of rectal cancer, which can overcome radiotherapy resistance by inhibiting DNA damage repair, affecting cell cycle, targeting delivery, enhancing DNA damage, and regulating tumor microenvironment, etc. In this article, complex coordination mechanism leading to radiotherapy resistance in rectal cancer was reviewed, current relevant studies on nanoparticles in improving radiotherapy response in rectal cancer were summarized, and the feasibility and future research direction of the combination of nanoparticles and radiotherapy in clinical treatment of rectal cancer were discussed.

Neoadjuvant chemoradiotherapy (NCRT) is the standard therapeutic strategy for locally advanced rectal cancer (LARC). Due to the different responses of patients to NCRT, the clinical prognosis of patients varies greatly. Therefore, it is important to establish sensitive biomarkers to predict the response of patients to treatments before NCRT. Immune cells in the tumor microenvironment (TME) were closely related to the efficacy of NCRT in patients with LARC. This paper reviewed the research progress on the relationships of cytotoxic T cells, programmed death-ligand 1 (PD-L1), tumor-associated macrophages (TAMs), regulatory T cells (Treg) and neutrophil to lymphocyte ratio (NLR) with chemoradiotherapy sensitivity in rectal cancer, illustrated the potential and limitations of these immune cells in predicting chemoradiotherapy response in rectal cancer, and provided a feasible direction for future researches.

Spinal cord injury (SCI) represents a complex pathophysiological process involving the interaction of multiple cell types. Conventional sequencing methods can only detect the average gene expression level of the damaged local cell populations, which is difficult to reflect its heterogeneity. Therefore, new technologies are needed to reveal the intercellular heterogeneity and the complex intercellular interactions of the damaged lesions. The single-cell RNA sequencing (scRNA-seq) technique facilitates high-resolution profiling of gene expression at the single-cell level, providing insights into cellular heterogeneity and function, potential molecular pathways, cell fate transitions, and the intercellular interactions pertinent to disease progression. This technology generates valuable gene expression data that support both basic and translational research efforts aiming at the identification of therapeutic targets for intervention. The scRNA-seq technique and its multifaceted application in the local immune microenvironment of injury after SCI were discussed, which will contribute to a more comprehensive understanding of the pathophysiological processes in the immune microenvironment of SCI.
Spinal Cord Injuries/genetics* ; Humans ; Single-Cell Analysis/methods* ; Sequence Analysis, RNA/methods* ; Animals ; Gene Expression Profiling/methods* ; Cellular Microenvironment/genetics*

Objective:To investigate the predictive value of blood routine and blood biochemical indicators for immunotherapy combined with chemotherapy-related interstitial pneumonia (IP) in patients with diffuse large B-cell lymphoma (DLBCL).Methods:The data of 151 newly-diagnosed DLBCL patients treated with rituximab combined with chemotherapy in the First Affiliated Hospital of Soochow University from December 2017 to October 2020 were retrospectively analyzed. According to whether IP occurred, the patients were divided into IP group and non-IP group. The patient's clinical data and baseline laboratory test results were collected. The differences in clinicopathological features and laboratory indicators between IP group and non-IP group were analyzed. In addition, the relationship between the variety of blood routine and blood biochemical indicators and the occurrence of IP was analyzed. The receiver operating characteristic (ROC) curve of the selected indicators to predict the occurrence of IP was drawn, and the predictive performance of each indicator was analyzed.Results:The incidence of IP was 9.3% (14/151) in DLBCL patients after receiving immunotherapy combined with chemotherapy. The lymphocyte count (LYM) in IP group at the first diagnosis was higher than that in non-IP group [1.60×10 9/L (1.40×10 9/L, 2.51×10 9/L) vs. 1.28×10 9/L (0.89×10 9/L, 1.78×10 9/L), U=-2.194, P=0.028], but there was no significant difference in the levels of platelet count, neutrophil count, monocyte count, lactate dehydrogenase (LDH), α-hydroxybutyrate dehydrogenase (α-HBDH), serum albumin (ALB) and the proportion of patients with elevated C-reactive protein (CRP) between the two groups (all P > 0.05). Compared with the laboratory indicators in non-IP group before the 4th cycle of treatment, LYM and ALB in IP group were significantly reduced at IP onset [0.72×10 9/L (0.46×10 9/L, 0.92×10 9/L) vs. 0.93×10 9/L (0.71×10 9/L, 1.15×10 9/L), 32.9 g/L (28.6 g/L, 34.9 g/L) vs. 40.3 g/L (36.1 g/L, 43.1 g/L)], but LDH and α-HBDH increased [332 U/L (255 U/L, 396 U/L) vs. 233 U/L (200 U/L, 286 U/L), 277 U/L (206 U/L, 315 U/L) vs. 189 U/L (159 U/L, 229 U/L)], and the differences were statistically significant (all P<0.05). The proportion of patients with elevated CRP in IP group was high than that in non-IP group [100.0% (14/14) vs. 56.9% (78/137), P=0.001]. The area under ROC curve of LYM, ALB, LDH and α-HBDH alone for predicting the occurrence of IP was 0.668, 0.820, 0.789 and 0.802. The best cut-off values of ALB, LDH and α-HBDH was 34.6 g/L, 241 U/L and 199 U/L. ALB had the highest sensitivity for predicting the occurrence of IP (81.8%). The areas under ROC curve of ALB+LDH, ALB+α-HBDH, LDH+α-HBDH, ALB+LDH+α-HBDH for predicting the occurrence of IP was 0.850, 0.844, 0.777 and 0.851, respectively. LDH+α-HBDH had the highest predictive sensitivity (92.9%), but the specificity was low (53.3%). The prediction sensitivity (both 78.6%) and specificity (both 86.1%) of ALB+LDH and ALB+LDH+α-HBDH were high. Conclusions:DLBCL patients are at risk of IP during immunotherapy combined with chemotherapy. The increased LYM at initial diagnosis is a risk factor for the occurrence of IP. The variety of LYM, ALB, LDH, α-HBDH and CRP during the treatment may be related to the occurrence of IP. Among them, ALB, LDH and α-HBDH have important predictive values for the occurrence of IP.

With the rise of domestic membrane anatomy and preliminary establishment of theoretical framework, the operation concepts supported by membrane anatomy are gaining popularity in surgery, especially in abdominal surgery. However, on account of a deep location and the complexity of organs and tissues around the pancreas and mesangial membrane, there is no unified understanding about the pancreas mesangial by experts and scholars. Meanwhile, few studies on it have been conducted. In addition, the location and extent of total mesangectomy based on the mesangial pancreatic theory are also controversial. The purpose of this article is to summarize the anatomy of pancreatic membrane and its application in surgery, in order to provide support for current studies on pancreatic mesangial anatomy.

With the rise of domestic membrane anatomy and preliminary establishment of theoretical framework, the operation concepts supported by membrane anatomy are gaining popularity in surgery, especially in abdominal surgery. However, on account of a deep location and the complexity of organs and tissues around the pancreas and mesangial membrane, there is no unified understanding about the pancreas mesangial by experts and scholars. Meanwhile, few studies on it have been conducted. In addition, the location and extent of total mesangectomy based on the mesangial pancreatic theory are also controversial. The purpose of this article is to summarize the anatomy of pancreatic membrane and its application in surgery, in order to provide support for current studies on pancreatic mesangial anatomy.

Objective To analyze the efficacy of higher pressure recompression therapy (≥70 m) in the patients with decompression sickness (DCS),who displayed poor efficacy after initial recompression.Methods Forty patients with type Ⅱ DCS who received treatment in our hospital from September 2011 to June 2018 were selected as research subjects,and were designated as the study group (n =6) and the control group (n =34),in accordance with whether or not they had received recompression therapy before admission into hospital.The DCS patients of the study group were those transferred to our hospital after initial lower pressure recompression treatment with unsatisfactory results.These patients were treated with the Air Diving DCS Recompression Treatment Table (Table 5,Oxygen Breathing) developed by the Chinese Naval Medical Research Institute,at a pressure of 70 meters and with a total oxygen breathing time of 225 minutes.The patients of the control group were those with type Ⅱ DCS patients who received initial recompression treatment in our hospital within the same time span.Delayed time,application rate and treatment efficacy in the patients of the 2 groups were analyzed statistically.Results The delayed time (14.5 ± 4.9 h) of the secondary recompression group (or the study group) was obviously longer than that of the control group(4.3 ± 3.0 h) (P ＜ 0.001),and there was statistical significance when comparisons were made between them (P ＜ 0.001).The application rate of higher pressure treatment profile in the secondary recompression group (83.3％) was higher than that of the control group (5.9％),also with statistical significance (P ＜ 0.001).The treatment efficacy of the 2 group was identical,without statistical significance (P =0.585).Conclusion The higher pressure recompression profile could effectively treat those DCS patients who showed unsatisfactory treatment effects after initial recompression.For those DCS patients with delayed treatment,proper recompression profile could also achieve satisfactory treatment outcome.With the lack of low pressure oxygen-breathing treatment profile and other supplementary treatment methods,secondary higher pressure recompression treatment should be performed as early possible,in the treatment of the patients with type Ⅱ DCS.

Objective To analyze the efficacy of higher pressure recompression therapy (≥70 m) in the patients with decompression sickness (DCS),who displayed poor efficacy after initial recompression.Methods Forty patients with type Ⅱ DCS who received treatment in our hospital from September 2011 to June 2018 were selected as research subjects,and were designated as the study group (n =6) and the control group (n =34),in accordance with whether or not they had received recompression therapy before admission into hospital.The DCS patients of the study group were those transferred to our hospital after initial lower pressure recompression treatment with unsatisfactory results.These patients were treated with the Air Diving DCS Recompression Treatment Table (Table 5,Oxygen Breathing) developed by the Chinese Naval Medical Research Institute,at a pressure of 70 meters and with a total oxygen breathing time of 225 minutes.The patients of the control group were those with type Ⅱ DCS patients who received initial recompression treatment in our hospital within the same time span.Delayed time,application rate and treatment efficacy in the patients of the 2 groups were analyzed statistically.Results The delayed time (14.5 ± 4.9 h) of the secondary recompression group (or the study group) was obviously longer than that of the control group(4.3 ± 3.0 h) (P ＜ 0.001),and there was statistical significance when comparisons were made between them (P ＜ 0.001).The application rate of higher pressure treatment profile in the secondary recompression group (83.3％) was higher than that of the control group (5.9％),also with statistical significance (P ＜ 0.001).The treatment efficacy of the 2 group was identical,without statistical significance (P =0.585).Conclusion The higher pressure recompression profile could effectively treat those DCS patients who showed unsatisfactory treatment effects after initial recompression.For those DCS patients with delayed treatment,proper recompression profile could also achieve satisfactory treatment outcome.With the lack of low pressure oxygen-breathing treatment profile and other supplementary treatment methods,secondary higher pressure recompression treatment should be performed as early possible,in the treatment of the patients with type Ⅱ DCS.

Objective To summarize clinical features of local and regional failure of salivary gland carcinoma treating by 125I seed,and evaluate the clinical and histologic risk factors for its development.Methods Patients with salivary gland carcinoma treated by 125I seeds between Oct 2001 and Aug 2012 were analyzed retrospectively.The risk factors were analyzed statistically,including age,gender,tumor site,TNM stage,histological differentiation,radiotherapy,treatment,matched peripheral dose and primary or recurrent tumor.Results Ninety-four of 449 patients with salivary gland carcinoma treated by 125I seeds developed local and/or regional area recurrence.Of these,six patients failed in both local and regional area,77 patients failed in local area and eleven patients failed in regional area.The local and regional failure rate was 20.9％.The result of multivariate analysis showed that surgery,radiotherapy and matched peripheral dose were the protective factors(OR =0.458,0.297,0.982,P ＜ 0.05),while age and TNM stage were the risk factors(OR =1.250,1.483,P ＜ O.05).Conclusions The local and regional failure rate was 20.9％.Surgery,radiotherapy and matched peripheral dose were the protective factors;age and TNM stage were the risk factors.